8-K: Vivos Therapeutics Reports Q1 2025 Financial Results, Highlights Strategic Shift with Sleep Center Acquisition

Vivos Therapeutics announces its Q1 2025 financial results, showcasing an 8% increase in product revenue and a 5% decrease in operating expenses, while strategically positioning itself with the pending acquisition of The Sleep Center of Nevada.

Summary

• Vivos Therapeutics reported a revenue of $3.0 million for Q1 2025, a decrease from $3.4 million in Q1 2024, which was expected due to a shift away from VIP service revenue.
• Product revenue increased by 8% year-over-year.
• Gross profit was $1.5 million, compared to $1.9 million in the same period last year.
• Gross margin decreased to 50% from 57% year-over-year.
• Operating expenses decreased by 5% to $5.4 million, reflecting cost-cutting measures.
• The net loss increased by 3% to $3.9 million.
• Cash and cash equivalents stood at $2.3 million as of March 31, 2025, with stockholders' equity at $4.4 million.
• Vivos sold 3,736 oral appliance arches in Q1 2025, generating approximately $1.8 million in revenue.
• Vivos entered into an agreement to acquire The Sleep Center of Nevada for up to $9 million in cash and stock, expected to close within two months.

Sentiment

Score: 6

Explanation: The sentiment is mixed. While there are positive aspects like increased product revenue and decreased operating expenses, the overall revenue and gross profit are down, and the net loss has increased. The acquisition of SCN is a positive strategic move, but it also introduces risks.

Positives

• Product revenue increased by 8% year-over-year, indicating growing demand for Vivos' products.
• Operating expenses decreased by 5%, showing improved cost management.
• The acquisition of The Sleep Center of Nevada is expected to provide access to thousands of OSA patients.
• Implementation of CPT medical codes simplifies reimbursement and billing processes.
• Vivos is engaging in discussions with several potential provider partners for profit-sharing alliances and potential acquisitions.

Negatives

• Overall revenue decreased from $3.4 million to $3.0 million due to the strategic shift away from VIP service revenue.
• Gross profit decreased from $1.9 million to $1.5 million.
• Gross margin decreased from 57% to 50%.
• Net loss increased by 3% to $3.9 million.
• Cash and cash equivalents decreased from $6.26 million to $2.3 million.

Risks

• The acquisition of SCN is subject to financing and integration risks.
• There is a risk that patients may not achieve the desired results from using Vivos products.
• Regulatory scrutiny and adverse publicity in the sleep apnea sector could pose risks.
• Vivos may be unable to secure additional financing on reasonable terms or maintain its Nasdaq listing.
• Market conditions could impact Vivos' business or ability to obtain financing.

Future Outlook

Vivos anticipates growth through its new marketing and distribution model, strategic alliances, and potential acquisitions of sleep-focused medical practices. The acquisition of SCN is expected to significantly impact future revenues and provide access to a large patient population.

Management Comments

• Kirk Huntsman, Vivos Chairman and Chief Executive Officer, stated that Vivos has strategically positioned itself for growth in 2025.
• Mr. Huntsman noted that the acquisition and integration of SCN will showcase Vivos' transformation.
• Mr. Huntsman stated that Vivos is at the forefront of a transformational opportunity in healthcare.

Industry Context

Vivos is operating in the sleep apnea treatment industry, which affects over 1 billion people worldwide. The company is positioning itself as an innovator in the field, offering non-surgical, non-invasive, and non-pharmaceutical solutions.

Comparison to Industry Standards

• It's difficult to provide a direct comparison without knowing the specific financial details of Vivos' competitors.
• However, companies like ResMed and Align Technology are major players in the sleep apnea and dental device markets, respectively.
• Vivos' focus on addressing the root causes of OSA and its FDA-cleared devices for both adults and children differentiate it from some competitors.
• The acquisition of The Sleep Center of Nevada is a strategic move to gain direct access to patients, similar to how some larger players integrate vertically.

Stakeholder Impact

• Shareholders may experience short-term volatility due to the mixed financial results and acquisition-related risks.
• Employees may be affected by the integration of SCN and ongoing cost-cutting measures.
• Patients could benefit from increased access to Vivos' treatments through the SCN acquisition.
• Providers may benefit from profit-sharing alliances and simplified reimbursement processes.

Next Steps

• Complete the acquisition of The Sleep Center of Nevada.
• Integrate SCN's business into Vivos' operations.
• Pursue strategic alliances and potential acquisitions of other sleep providers.
• Continue to drive adoption of Vivos' FDA-cleared devices.
• Monitor the impact of CPT medical codes on reimbursement and billing.

Key Dates

Keywords

Vivos Therapeutics, Sleep Apnea, Financial Results, Acquisition, Medical Device, Revenue, Operating Expenses, Net Loss, Sleep Center of Nevada, OSA, Oral Appliance